Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial

N Nishimoto, K Yoshizaki, N Miyasaka… - … : Official Journal of …, 2004 - Wiley Online Library
Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response,
inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in …

[HTML][HTML] Structure and function of a new STAT-induced STAT inhibitor

…, T Matsumoto, S Minamoto, A Aono, N Nishimoto… - Nature, 1997 - nature.com
The signalling pathway that comprises JAK kinases and STAT proteins (for signal transducer
and activator of transcription) is important for relaying signals from various cytokines …

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease

K Yoshizaki, T Matsuda, N Nishimoto, T Kuritani… - 1989 - ashpublications.org
Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma
cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma …

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

…, T Murata, M Miyoshi, M Tomiita, N Nishimoto… - The Lancet, 2008 - thelancet.com
Background Systemic-onset juvenile idiopathic arthritis does not always respond to available
treatments, including antitumour necrosis factor agents. We investigated the efficacy and …

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader …

N Nishimoto, J Hashimoto, N Miyasaka… - Annals of the …, 2007 - ard.bmj.com
Objective: To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody)
monotherapy to inhibit progression of structural joint damage in patients with RA. Methods: In a …

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

N Nishimoto, Y Kanakura, K Aozasa, T Johkoh… - Blood, 2005 - ashpublications.org
Multicentric Castleman disease (MCD) is an atypical lymphoproliferative disorder characterized
by systemic lymphadenopathy and constitutional inflammatory symptoms. Dysregulated …

[PDF][PDF] TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling

…, S Strand, R Kiesslich, S Huber, H Ito, N Nishimoto… - Immunity, 2004 - cell.com
Alterations of TGF-β signaling have been described in colorectal cancer, although the molecular
consequences are largely unknown. By using transgenic mice overexpressing TGF-β or …

Interleukin 6: from bench to bedside

N Nishimoto, T Kishimoto - Nature clinical practice Rheumatology, 2006 - nature.com
Interleukin (IL)-6 is a pleiotropic cytokine that has important roles in the regulation of the
immune response, inflammation, and hematopoiesis. Disruption of IL-6 regulation might, …

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody …

N Nishimoto, K Terao, T Mima… - Blood, The Journal …, 2008 - ashpublications.org
Interleukin-6 (IL-6) plays pathologic roles in immune-inflammatory diseases such as rheumatoid
arthritis (RA) and Castleman disease. By inhibiting IL-6 receptors (IL-6Rs), tocilizumab (…

[HTML][HTML] The paradigm of IL-6: from basic science to medicine

T Naka, N Nishimoto, T Kishimoto - Arthritis Research & Therapy, 2002 - Springer
Chapter summary IL-6 is a pleiotropic cytokine with a wide range of biological activities in
immune regulation, hematopoiesis, inflammation, and oncogenesis. Its activities are shared by …